SenesTech Launches ContraPest® Fertility Control Product “Research Sales”

FLAGSTAFF, Ariz., Dec. 14, 2016 — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, today announced the launch of ContraPest “research sales” as part of its “go to market” strategy for commercializing its lead product.

On August 2, 2016, SenesTech received registration from the U.S. EPA for its first product, ContraPest®. This registration, the first for a non-lethal fertility control product for managing rat populations, now allows for the marketing of ContraPest in the U.S., and is globally seen as the first new product with the potential to effectively address rat infestations.

The Company has adopted a “research sales” policy with key potential customers to research the deployment and use of ContraPest in customer specific settings such as housing projects and subway stations, while generating revenue to the Company. Initial research sales are already underway in Washington and Louisiana, while potential customer projects are under discussion in New York City, New Jersey, Georgia, and California. SenesTech is also pursuing opportunities outside the U.S. in the United Kingdom, Germany, and Australia.

“It is key that we work closely with the early adopters of our fertility control technology,” said Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech. “We are changing the paradigm of pest control, reducing the use of poisons with a safer, more sustainable solution. We continue to learn how best to do this with these early adopters while adding this approach to their integrated pest management plans. This strategy allows a scientific product learning cycle, as well as generating cash flow for further growth. We can also use this model to more rapidly respond to urgent global infestations, such as those rapidly emerging in Paris.”

About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company’s first fertility control product candidate, ContraPest®, will be marketed for use initially in controlling rat infestations. ContraPest’s novel technology and approach targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated, and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a

high risk of environmental contamination and the poisoning of non-target animals, pets and children.

The Company believes its non-lethal approach targeting reproduction is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations. The Company believes ContraPest® will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticides. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/senestech-launches-contrapest-fertility-control-product-research-sales-300377918.html

SOURCE SenesTech, Inc.